Learn About Primary Localized Cutaneous Amyloidosis
Primary localized cutaneous amyloidosis (PLCA) is a condition in which clumps of abnormal proteins called amyloids build up in the skin, specifically in the wave-like projections (dermal papillae) between the top two layers of skin (the dermis and the epidermis). The primary feature of PLCA is patches of skin with abnormal texture or color. The appearance of these patches defines three forms of the condition: lichen amyloidosis, macular amyloidosis, and nodular amyloidosis.
PLCA can be caused by mutations in the OSMR or IL31RA gene. When caused by an OSMR gene mutation, the condition is classified as type 1, while an IL31RA gene mutation causes type 2. Mutations in either gene are likely involved in lichen and macular amyloidosis, which are thought to be related conditions that arise through similar disease mechanisms. The genetic basis of nodular amyloidosis is unknown.
PLCA occurs worldwide, most commonly in Southeast Asia and South America. The prevalence of the condition is unknown.
In most cases, PLCA is not inherited and occurs in people with no history of the condition in their family.
University Medical Associates Of The Medical University Of South Carol
Daniel Judge is an Advanced Heart Failure and Transplant Cardiologist and a Cardiologist in Charleston, South Carolina. Dr. Judge is rated as a Distinguished provider by MediFind in the treatment of Primary Localized Cutaneous Amyloidosis. His top areas of expertise are Cardiomyopathy, Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Heart Transplant, and Cardiac Ablation. Dr. Judge is currently accepting new patients.
Taige Cao practices in Singapore, Singapore. Cao is rated as an Elite expert by MediFind in the treatment of Primary Localized Cutaneous Amyloidosis. Their top areas of expertise are Primary Localized Cutaneous Amyloidosis, Fox-Fordyce Disease, Porphyria Cutanea Tarda, and Primary Amyloidosis.
Ping Lu practices in Kaifeng, China. Lu is rated as an Elite expert by MediFind in the treatment of Primary Localized Cutaneous Amyloidosis. Their top areas of expertise are Primary Localized Cutaneous Amyloidosis, Primary Amyloidosis, Memory Loss, and Generalized Tonic-Clonic Seizure.
Summary: The aim of this clinical trial is to find out whether the combination of tocilizumab tablets and acitretin capsules is more effective than acitretin capsules alone in treating primary cutaneous amyloidosis. It will also investigate the safety of the combination of tocilizumab tablets and acitretin capsules. The main questions it aims to answer are: 1. Does the combination of tocilizumab tablets an...
Published Date: March 01, 2017
Published By: National Institutes of Health